Publication:
Soy Isoflavones in the Management of Postmenopausal Osteoporosis

dc.authorscopusid13407057000
dc.authorscopusid7005378599
dc.authorscopusid7003524225
dc.authorscopusid57217186876
dc.contributor.authorAtmaca, Ayşegül
dc.contributor.authorKleerekoper, M.
dc.contributor.authorBayraktar, M.
dc.contributor.authorKüçük, O.
dc.date.accessioned2020-06-21T15:13:32Z
dc.date.available2020-06-21T15:13:32Z
dc.date.issued2008
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Atmaca] Ayşegül, Department of Internal Medicine, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Kleerekoper] Michael, Department of Internal Medicine, Trinity Health Ann Arbor Hospital, Ypsilanti, MI, United States, Wayne State University School of Medicine, Detroit, MI, United States; [Bayraktar] Miyase, Division of Endocrinology, Hacettepe Üniversitesi, Ankara, Turkey; [Küçük] Ömer Nuriye Nuriye, Wayne State University, Detroit, MI, United States, Barbara Ann Karmanos Cancer Institute, Detroit, MI, United Statesen_US
dc.description.abstractThis is a review article designed to address the effects of soy isoflavones on bone metabolism in postmenopausal women and their place in the prevention and treatment of postmenopausal osteoporosis. Soy isoflavones are natural products that could be used as an alternative to menopausal hormone therapy because they are structurally and functionally related to 17β-estradiol. In vitro and animal studies have shown that they act in multiple ways to exert their bone-supporting effects. They act on both osteoblasts and osteoclasts through genomic and nongenomic pathways. Epidemiological studies and clinical trials suggest that soy isoflavones have beneficial effects on bone mineral density, bone turnover markers, and bone mechanical strength in postmenopausal women. However, there are conflicting results related to differences in study design, estrogen status of the body, metabolism of isoflavones among individuals, and other dietary factors. The long-term safety of soy isoflavone supplements remains to be demonstrated. Copyright © 2008 The North American Menopause Society.en_US
dc.identifier.doi10.1097/gme.0b013e31815c1e7f
dc.identifier.endpage757en_US
dc.identifier.isbn9780123694430
dc.identifier.issn1072-3714
dc.identifier.issn1530-0374
dc.identifier.issue4en_US
dc.identifier.pmid18277912
dc.identifier.scopus2-s2.0-51449102952
dc.identifier.scopusqualityQ1
dc.identifier.startpage748en_US
dc.identifier.urihttps://doi.org/10.1097/gme.0b013e31815c1e7f
dc.identifier.volume15en_US
dc.identifier.wosWOS:000257501000025
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofMenopause-The Journal of the Menopause Societyen_US
dc.relation.journalMenopause-The Journal of the North American Menopause Societyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBone Mineral Densityen_US
dc.subjectMenopauseen_US
dc.subjectOsteoporosisen_US
dc.subjectPhytoestrogensen_US
dc.subjectSoy Isoflavonesen_US
dc.titleSoy Isoflavones in the Management of Postmenopausal Osteoporosisen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files